LobbyingAngiosafe lobbying by quarter
Angiosafe's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q1 2026; the issues it reports most are Health Issues and Medicare/Medicaid.
Angiosafe
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 3 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2026
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$0 · 2 reports
- Medicare and Medicaid$0 · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)2 reports
- Health & Human Services, Dept of (HHS)2 reports
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Liberty Partners Group | $0 | 2 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Liberty Partners Group | Under $5,000 |
| 07/20for Q2 | Liberty Partners Group | Under $5,000 |
| 04/17for Q1 | Liberty Partners Group | Under $5,000 |
| 02/13for Q1 | Liberty Partners Group | Under $5,000 |